Serial Biomarkers Optimize Antibiotic Utilization in Hospital-Acquired Pneumonia

A narrative review published in Antimicrobial Resistance & Infection Control reports that the clinical utility of biomarkers such as procalcitonin and C-reactive protein in hospital-acquired pneumonia depends on serial kinetic monitoring rather than static, point-in-time diagnostic evaluations. Despite decades of biomarker investigation in sepsis, research has not produced consistent practice modifications for hospital-acquired pneumonia, which persists as one of the most consequential healthcare-associated infections. The authors note that the condition imposes significant burdens regarding patient morbidity, mortality, and antimicrobial pressure within inpatient facilities, while diagnostic integration into daily routines remains uneven and subject to unappreciated clinical limitations.

According to the review, the clinical management of hospital-acquired pneumonia is substantially challenged by diagnostic imprecision and marked pathogen heterogeneity, including an elevated burden of multidrug-resistant organisms. Although biomarkers have entered medical practice as adjunctive resources designed to assist diagnostic frameworks and support antimicrobial stewardship, the foundational research supporting these strategies stems predominantly from investigations in ventilator-associated pneumonia, severe community-acquired pneumonia, or mixed sepsis cohorts. Consequently, because the vast majority of hospital-acquired pneumonia episodes occur among non-ventilated patients, biomarker-directed management approaches remain largely uninvestigated within this primary clinical population.

To address these gaps, the authors structure their evaluation across the complete continuum of hospital-acquired pneumonia care—encompassing diagnostic adjunction, treatment monitoring, antimicrobial de-escalation, and final discontinuation—by utilizing a clinical function-based framework adapted from the NIH/FDA BEST taxonomy. The review argues that the practical efficacy of biomarker-guided treatment-duration protocols is fundamentally context-dependent, showing diminishing clinical value in settings where baseline antibiotic prescribing practices already align with recommended standards. Conversely, biomarker guidance provides demonstrable clinical utility under conditions where empirical antibiotic regimens are routinely prolonged beyond established treatment benchmarks.

The evaluation critically assesses evidence from landmark clinical trials, specifically highlighting findings from the PASS and ADAPT-SEPSIS investigations. In these studies, biomarker-directed protocols either failed to demonstrate superiority over already-adequate standard medical care or paradoxically resulted in increased overall antibiotic exposure for patients. The authors contrast these adverse or neutral trial outcomes with structured kinetic-guided discontinuation algorithms, including double-trigger models integrated into digital clinical decision support systems, which successfully shortened therapeutic courses without compromising patient safety.

Ultimately, the authors present a conditional endorsement of biomarker implementation in hospital-acquired pneumonia rather than an outright dismissal of these monitoring tools. Under this synthesis, the true clinical advantage of biomarkers relies heavily on pre-existing institutional prescribing patterns, reliance on kinetic trajectory rather than rigid threshold-based cutoffs, and seamless integration alongside an individual patient’s overall clinical course rather than serving as a replacement for clinical judgment. The authors emphasize that the immediate clinical priority involves correctly interpreting and integrating existing biomarkers within longitudinal clinical trajectories, while dedicated clinical evaluations are still required to determine whether these principles apply to non-ventilated hospital-acquired pneumonia.

Subject of Research: Biomarker kinetics and antibiotic stewardship in hospital-acquired pneumonia

Article Title: How to apply biomarkers to optimize antibiotic utilization in hospital-acquired pneumonia?

Article References: Cidade, J. P., Coelho, L., De Bus, L., De Pascale, G., Gradel, K. O., Guerreiro, G., Lisboa, T., Martin-Loeches, I., Millot, G., Morris, A. C., Nobre, V., Nseir, S., Roger, C., Salluh, J., Sweeney, D. A., & Póvoa, P. (2026). How to apply biomarkers to optimize antibiotic utilization in hospital-acquired pneumonia?. Antimicrobial Resistance & Infection Control. https://doi.org/10.1186/s13756-026-01856-y

Image Credits: AI Generated

DOI: 10.1186/s13756-026-01856-y

Keywords: hospital-acquired pneumonia, biomarkers, antibiotic stewardship, procalcitonin, C-reactive protein, kinetic monitoring, antimicrobial resistance, clinical decision support, apply, optimize, antibiotic, utilization